000182715 001__ 182715
000182715 005__ 20240229145728.0
000182715 0247_ $$2doi$$a10.1038/s41419-022-05421-4
000182715 0247_ $$2pmid$$apmid:36400754
000182715 0247_ $$2altmetric$$aaltmetric:138609175
000182715 037__ $$aDKFZ-2022-02873
000182715 041__ $$aEnglish
000182715 082__ $$a570
000182715 1001_ $$aDarawshi, Odai$$b0
000182715 245__ $$aAn mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
000182715 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2022
000182715 3367_ $$2DRIVER$$aarticle
000182715 3367_ $$2DataCite$$aOutput Types/Journal article
000182715 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1669037569_9222
000182715 3367_ $$2BibTeX$$aARTICLE
000182715 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182715 3367_ $$00$$2EndNote$$aJournal Article
000182715 520__ $$aMultiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a key metabolic regulator, which frequently becomes dysregulated in cancer. While mTORC1 inhibitors reduce MM viability and synergize with other therapies in vitro, clinically, mTORC1 inhibitors are not effective for MM. Here we show that the inactivation of mTORC1 is an intrinsic response of MM to PI treatment. Genetically enforced hyperactivation of mTORC1 in MM was sufficient to compromise tumorigenicity in mice. In vitro, mTORC1-hyperactivated MM cells gained sensitivity to PIs and hypoxia. This was accompanied by increased mitochondrial stress and activation of the eIF2α kinase HRI, which initiates the integrated stress response. Deletion of HRI elevated the toxicity of PIs in wt and mTORC1-activated MM. Finally, we identified the drug PMA as a robust inducer of mTORC1 activity, which synergized with PIs in inducing MM cell death. These results help explain the clinical inefficacy of mTORC1 inhibitors in MM. Our data implicate mTORC1 induction and/or HRI inhibition as pharmacological strategies to enhance MM therapy by PIs.
000182715 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000182715 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182715 7001_ $$aMuz, Barbara$$b1
000182715 7001_ $$aNaamat, Shiri Gershon$$b2
000182715 7001_ $$aPraveen, Bellam$$b3
000182715 7001_ $$aMahameed, Mohamed$$b4
000182715 7001_ $$aGoldberg, Karin$$b5
000182715 7001_ $$aDipta, Priya$$b6
000182715 7001_ $$aShmuel, Miriam$$b7
000182715 7001_ $$aForno, Francesca$$b8
000182715 7001_ $$00000-0003-0202-4906$$aBoukeileh, Shatha$$b9
000182715 7001_ $$aPahima, Hadas$$b10
000182715 7001_ $$0P:(DE-He78)ef011d4044908051e4d6f0c96e150106$$aHermann, Julia$$b11$$udkfz
000182715 7001_ $$aRaab, Marc S$$b12
000182715 7001_ $$aPoos, Alexandra M$$b13
000182715 7001_ $$aWeinhold, Niels$$b14
000182715 7001_ $$aRosenbluh, Chaggai$$b15
000182715 7001_ $$aGatt, Moshe E$$b16
000182715 7001_ $$0P:(DE-He78)c8525dbb77cddc5280375ea4a5e3c13e$$aPalm, Wilhelm$$b17$$udkfz
000182715 7001_ $$00000-0002-6371-2780$$aAzab, Abdel Kareem$$b18
000182715 7001_ $$00000-0001-8067-6577$$aTirosh, Boaz$$b19
000182715 773__ $$0PERI:(DE-600)2541626-1$$a10.1038/s41419-022-05421-4$$gVol. 13, no. 11, p. 969$$n11$$p969$$tCell death & disease$$v13$$x2041-4889$$y2022
000182715 909CO $$ooai:inrepo02.dkfz.de:182715$$pVDB
000182715 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef011d4044908051e4d6f0c96e150106$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000182715 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c8525dbb77cddc5280375ea4a5e3c13e$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000182715 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000182715 9141_ $$y2022
000182715 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000182715 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELL DEATH DIS : 2021$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:53Z
000182715 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:53Z
000182715 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-14T16:18:53Z
000182715 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000182715 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELL DEATH DIS : 2021$$d2022-11-17
000182715 9201_ $$0I:(DE-He78)A330-20160331$$kA330$$lA330 NWG Signaltransduktion und Stoffwechsel der Zelle$$x0
000182715 980__ $$ajournal
000182715 980__ $$aVDB
000182715 980__ $$aI:(DE-He78)A330-20160331
000182715 980__ $$aUNRESTRICTED